Jaktinib
- Generic Name
- Jaktinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. Jaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).
- Associated Conditions
- -
- Associated Therapies
- -
Atopic Dermatitis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, and Companies
The Atopic Dermatitis market, valued at USD 17 billion in 2023 across 7MM, is projected to grow by 2034. Key players include Sanofi/Regeneron, Pfizer, and Eli Lilly, with promising therapies like Baricitinib and Dupilumab. The market is driven by novel treatments and increased awareness, addressing a prevalent population of over 32 million cases in the US alone.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath